Sao Tome and Principe vs Vanuatu: The number of people with susceptibility test result for rifampicin
Sao Tome and Principe
0
in 2021
Vanuatu
0
in 2021
Sao Tome and Principe rank
142nd
Vanuatu rank
142nd
The number of people with susceptibility test result for rifampicin over time
- Sao Tome and Principe
- Vanuatu
How they compare
Sao Tome and Principe currently reports 0 against 0 in Vanuatu, a difference of 0.
Across all 5 years both countries report, Vanuatu has been ahead every year.
Sao Tome and Principe ranks 142nd and Vanuatu ranks 142nd of 146 countries.
Vanuatu has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Sao Tome and Principe | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.76 | 99.29 | 78.53 | Vanuatu |
| 2020s | 1.04 | 46.74 | 45.7 | Vanuatu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Sao Tome and Principe or Vanuatu?
- Sao Tome and Principe, at 0 against 0 in Vanuatu as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Sao Tome and Principe and Vanuatu?
- 0, with Sao Tome and Principe ahead.
- How many years of comparable data are there for Sao Tome and Principe and Vanuatu?
- 5 years are reported by both, from 2017 to 2021.
- How do Sao Tome and Principe and Vanuatu rank globally for the number of people with susceptibility test result for rifampicin?
- Sao Tome and Principe ranks 142nd and Vanuatu ranks 142nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.